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Rat serosal mast cells, which  synthesize only heparin 
proteoglycans as detected by intrinsic labeling with 
[”’S]sulfate, were analyzed  for  the  presence of intra- 
cellular  chondroitin  sulfate proteoglycans by chemical 
and immunochemical means. Rat  serosal mast cells of 
~ 9 9 %  purity  were  treated  with  Zwittergent 3-12 and 
4 M guanidine HCl, and  the  extracted nonradiolabeled 
proteoglycans were  purified by density  gradient cen- 
trifugation. As assessed by quantification of the  unsat- 
urated  disaccharides released from the proteoglycans 
by chondroitinase ABC treatment, lo6 rat serosal mast 
cells contained 2.4-4.5 pg of chondroitin  sulfate pro- 
teoglycans. Analysis of the chondroitinase ABC digests 
by high performance  liquid  chromatography  revealed 
the  unsaturated  disaccharides ADi-4S,  ADi-diSB, and 
ADi-diSE which were  derived  from GlcAdGalNAc-4- 
SO,, iduronic acid-2-S04~GalNAc-4-S04, and GlcA.-, 
GalNAc-4,6-diS04, respectively. The molar ratio of the 
monosulfated to disulfated disaccharides was -2:l 
with hDi-diSE > ADi-diSB.  When analyzed with a 
mouse anti-chondroitin sulfate monoclonal antibody 
and fluorescein-labeled F(ab’)a goat anti-mouse IgG, 
-91% of permeabilized and  chondroitinase ABC- 
treated cells in the mast cell preparations exhibited 
intracellular fluorescence, and  the  pattern of staining 
indicated that  the chondroitin  sulfate molecules were 
located in  the  secretory  granules.  The specificity of the 
monoclonal antibody  for  the  unsaturated double bond 
created by chondroitinase ABC treatment of the  pro- 
teoglycan in situ was established by the absence of 
fluorescence when the chondroitinase ABC step was 
omitted or when heparinase digestion was  substituted 
for chondroitinase ABC. Furthermore,  the  ability of 
the anti-chondroitin sulfate monoclonal antibody to 
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mediate fluorescence in  situ was  markedly reduced by 
absorption  with solid-phase chondroitin  sulfate proteo- 
glycan that had been chondroitinase ABC-treated, but 
not by absorption with undigested proteoglycan or 
with solid-phase heparin. The highly sulfated chon- 
droitin  sulfate proteoglycans of rat serosal mast cells 
are the same type synthesized by the rat mucosal mast 
cell subclass. The simultaneous presence of both hepa- 
rin and  chondroitin  sulfate glycosaminoglycans in rat 
serosal mast cells in the absence of detectable chon- 
droitin  sulfate  synthesis suggests that  this chondroitin 
sulfate-containing proteoglycan is a remnant of an  ear- 
lier  stage of differentiation  and implies an ontologic 
relationship between the  two mast cell subclasses. 
Distinct  subpopulations of mast cells in  the  rat  have  been 
identified by the differences in  the  types of proteoglycans (1, 
2) and  serine  proteases (3, 4) that  they  synthesize  and  store 
in  their  secretory granules,  by their  differential  histochemical 
staining properties (5) ,  by their relative histamine content 
per cell (6,7), by the  presence or absence of T-cell dependence 
for maintenance (8), and by the relative ability of various 
agonists to  elicit release of preformed  intragranular  mediators 
(7) .  Mast cells obtained  from  the serosal surfaces of the  rat 
peritoneal cavity incorporate [35S]sulfate into a protease- 
resistant M, 750,000 heparin proteoglycan (l), whereas T- 
cell-dependent mast cells isolated from the mucosa of the 
small intestine of Nippostrongylus brasiliensis-infected rats 
incorporate [35S]sulfate into a protease-resistant M, 150,000 
chondroitin sulfate proteoglycan (2). When  the  chondroitin 
sulfate proteoglycans from  rat mucosal mast cells are  incu- 
bated with chondroitinase ABC and the generated unsatu- 
rated  disaccharides  are  analyzed by high performance liquid 
chromatography (HPLC’), the three disaccharides ADi-4S, 
ADi-diSB, and ADi-diSE are  detected with the  concentration 
of ADi-4S = ADi-diSB > ADi-diSE. Although rat serosal mast 
cells do  not  synthesize  detectable levels of 35S-labeled chon- 
droitin sulfate proteoglycans ex vivo, they synthesize chon- 
droitin sulfate glycosaminoglycans that are rich in Di-diSE 
onto  the exogenous  glycosaminoglycan  acceptor, p-nitro- 
phenyl-/3-D-xyloside, during  short-term  culture (9). 
We now demonstrate by  chemical techniques  that  rat  ser- 
osal mast cells have chondroitin sulfate proteoglycans and 
that  their  chondroitin  sulfate glycosaminoglycans contain  the 
same types of unique disulfated disaccharides that are de- 
tected by “S-labeling of rat mucosal mast cells. Furthermore, 
using a novel monoclonal anti-chondroitin sulfate antibody 
for intracellular immunofluorescence staining, we have deter- 
mined  that  the  chondroitin  sulfate molecules are  in essentially 
all  rat  serosal  mast cells and  are located intragranularly. 
EXPERIMENTAL PROCEDURES 
Chemical Characterization of Chondroitin Sulfate in Rat Serosal 
Mast Cells-Rat serosal mast cells were obtained by lavage of the 
The abbreviations used are: HPLC, high performance liquid chro- 
matography; ADi-4S,  ADi-GS,  ADi-diSB, ADi-diSD, and ADi-diSE, the 
unsaturated disaccharides derived from GlcA-GalNAc-4-SO4, 
GlcA4alNAc-6-S04, iduronic acid-2-S04+GalNAc-4-S0,, GlcA-2- 
S044alNAc-6-S04,  and GlcA+GalNAc-4,6-d1SO~, respectively; 
HBSS, Hanks’ balanced salt solution. 
13393 
13394 Chondroitin Sulfate Proteoglycans in Rat Serosal Mast Cells 
peritoneal cavity of each rat with 30 ml  of Tyrode's buffer containing 
1 mg/ml gelatin. The mast cells were concentrated to >99% purity 
by one isopyknic (1) and two isokinetic (10) centrifugations. Each 
preparation of  1.1-1.3 X 10' highly purified mast cells from 100 rats 
was suspended in 150 p1 of 1% (w/v) Zwittergent 3-12 (Behring 
Diagnostics) for -15 s and then in 12 ml of 4 M guanidine HCl 
containing 0.01 M Tris-HC1 and CsCl, pH 7.0 (final density = 1.4  g/ 
ml) (11). The mast cell extracts were centrifuged for 48 h at -100,000 
X g ,  and  the bottom halves of the gradients were dialyzed sequentially 
against 1 M sodium acetate followed by  0.1 M ammonium bicarbonate; 
the dialyzed samples were lyophilized and resuspended in 2 ml of 
H20. The total amount of proteoglycan in each preparation was 
quantified by determining the uronic acid content of  5-25 p1 of the 
density gradient-purified samples by the carbazole technique (12). To 
determine the amount of chondroitin sulfate, 100-150-pl samples 
were suspended in  5 mM Tris-HCI,  5 mM sodium acetate,  5 mM NaCl, 
and 0.01% bovine serum albumin (enriched-Tris buffer), and were 
incubated with or without 0.05 unit of chondroitinase ABC (Miles 
Laboratories) for 30 min at 37 'C. The chondroitinase ABC digests 
were analyzed for changes in their absorbance at 232 nm, and  the 
amount of chondroitin  sulfate was calculated by the method of Saito 
et al. (13) using an extinction coefficient of B.l/pmol for the generated 
unsaturated disaccharides. Replicate chondroitinase ABC-treated 
samples were each made 80% in  ethanol, placed in an ice bath for 30 
min, and centrifuged at 8,000 X g for 5 min at 4 "C. The unsaturated 
disaccharides in the ethanol  extract were then resolved by HPLC  and 
quantified by monitoring the eluate at 232 nm (14). The unsaturated 
disaccharides derived from G1cA-2-SO4+GalNAc-6-SO4 (ADi-diSD) 
and ADi-diSE were prepared from shark cartilage and squid cartilage 
chondroitin sulfates, respectively, and were used as standards. In 
some preparations, the amount of chondroitin sulfate in the samples 
was also estimated by its integrated absorbance relative to  that of 
known amounts of  ADi-GS, the  unsaturated disaccharide derived from 
GlcA+GalNAc-6-S04 (Miles), which  was coinjected with the sample. 
Immunologic Demonstration of Chondroitin  Sulfate in Isolated Rat 
Serosal Mast Cells-An intracellular immunofluorescent technique 
employing monoclonal antibodies was used to determine the percent- 
age of the cells in the  rat serosal mast cell population that contained 
intragranular chondroitin sulfate proteoglycans. The monoclonal an- 
tibody used (5/29/2-B-6) was of the IgG, subclass and was obtained 
by immunizing mice with chondroitinase ABC-treated bovine nasal 
cartilage proteoglycan (15). This high affinity antibody  has analogous 
specificity with two other monoclonal antibodies (4/8/9-A-2 and 4/ 
8/2-B-4) that specifically recognize oligosaccharides containing  non- 
reducing terminal disaccharides of ADi-4S (15, 16). Purified rat 
serosal mast cells were suspended in Hanks' balanced salt solution 
(HBSS)  and were permeabilized by the addition of absolute ethanol 
to a  final  concentration of 90% (v/v).  The permeabilized mast cells 
were spread on cytocentrifuge slides and treated with HBSS, 0.25 
unit of chondroitinase ABC in HBSS, or 25 units of heparinase 
(Miles) in HBSS for 15 min at 37 "C. Following two washes with 
HBSS containing 0.1% bovine serum albumin and 0.02% sodium 
azide (H/B/A), the mast cells were incubated for 15 min at 25 "C 
with a saturating dilution (6.6 pg/ml mouse IgGJ of either the  anti- 
chondroitin  sulfate monoclonal antibody  or an equal dilution of an 
anti-keratan sulfate monoclonal antibody, 1/20/5-D-4 (16). The cell 
preparations were washed twice with H/B/A, and incubated for 5 
min at 25 "C with a 1:80 dilution of fluorescein-conjugated F(ab')z 
goat anti-mouse IgG (Cooper Biomedical, Malvern, PA). Following 
two additional washes with H/B/A, a drop of phosphate-buffered 
saline/glycerol (L1, v/v) was placed over the cells, and  the prepara- 
tions were covered with coverslips. The mast cells were photographed 
with a Leitz Orthoplan epi-illumination fluorescence microscope also 
equipped for Nomarski interference  contrast microscopy. The  anti- 
keratan  sulfate monoclonal antibody was chosen as a negative control 
reagent because rat serosal mast cells do not contain detectable 
amounts of this glycosaminoglycan and because this antibody is of 
the same subclass as  the anti-chondroitin  sulfate antibody. 
Heparin-agarose (Sigma) and chondroitin sulfate proteoglycan- 
Sepharose 4B  were used as affinity resins to ensure the specificity of 
the 5/29/2-B-6 monoclonal antibody. Sixteen mg  of rat chondrosar- 
coma chondroitin sulfate proteoglycans were dissolved in 20 ml of 
coupling buffer (0.5 M NaCI, 0.1 M NaHC03,  pH 8.3) and incubated 
overnight a t  4 "C with 1 g of cyanogen bromide-activated Sepharose 
4B (Sigma). The gel  was separated from the  supernatant by centrif- 
ugation. As assessed by a decrease in the uronic acid content in the 
supernatant,  it was estimated that -25% of the added chondrosar- 
coma chondroitin sulfate proteoglycans were coupled to the resin. 
The coupled  gel  was incubated for 2 h at 25 "C with 1 M ethanolamine, 
pH 8.0, and  then was washed five times on a  sintered glass funnel 
alternately with coupling buffer and 0.5 M NaCI,  0.1 M sodium acetate, 
pH 4.0.  Two  ml of chondroitin sulfate proteoglycan-Sepharose affin- 
ity resin were suspended in  enriched-Tris buffer with protease inhib- 
itors (17) and incubated with 1 unit of chondroitinase ABC for 30 
min at 37 "C; the digestion was stopped by washing the gel with 
HBSS. Samples (100 pl)  of the 5/29/2-B-6 antibody (6.6 pg  of IgG,/ 
ml) were mixed for 1 h at room temperature with 25 pl of packed 
chondroitin sulfate proteoglycan-Sepharose (containing an estimated 
12 pg of chondroitin sulfate glycosaminoglycans), 25 p1 of packed 
chondroitin sulfate proteoglycan-Sepharose that had been treated 
with chondroitinase ABC, or 15.7 p1 of packed heparin-agarose (con- 
taining an estimated 12 pg  of heparin glycosaminoglycans). The 
supernatants were  recovered by centrifugation and  the capacities of 
serial dilutions of these supernatants  to exhibit intracellular immu- 
nofluorescent staining of permeabilized, chondroitinase ABC-treated 
rat serosal mast cells were compared to each other and  to similar 
dilutions of unabsorbed antibody. 
RESULTS 
Chemical Characterization of Chondroitin Sulfate in Rat 
Serosal Mast Cells-As assessed by the carbazole reaction,  the 
density  gradient-purified  extracts  contained -25  pg of uronic 
acid per lo6 rat  serosal  mast cells. Incubating 200 pg of this 
material with chondroitinase ABC resulted in a 0.405 net 
change in absorbance at 232 nm. Based on the reported 
extinction coefficient of ADi-4S, samples from two separate 
experiments  contained -43 and -27 pg of chondroitin  sulfate, 
thereby allowing the  estimate  that lo6 rat serosal mast cells 
contained 4.5 & 1.0 pg (mean & range, n = 2) of chondroitin 
sulfate proteoglycans. 
Resolution by HPLC of the  unsaturated  disaccharides  in 
the  chondroitinase ABC digests of density  gradient-purified 
proteoglycans  revealed peaks of absorbance at  retention  times 
of 8.9, 12.8, and 13.8 min (Fig. l ) ,  corresponding to the 
respective standards ADi-4S, ADi-diSB, and ADi-diSE. As the 
resolution between the ADi-diSB and ADi-diSE unsaturated 
disaccharides was not complete, the  ratio of ADi-4S to  the 
sum of the disulfated disaccharides was analyzed in three 
separate  experiments,  with  the  results being 2.3:l.O (Fig. l ) ,  
1.4:1.0, and 2.0:l.O. In  each case, the findings were comparable 
to Fig. 1 in that the quantity of ADi-diSE was somewhat 
greater  than ADi-diSB. By comparing  the relative areas of the 
ADi-6S and ADi-4S peaks when  known amounts of ADi-6S 
were co-injected  with another  aliquot of this  sample,  it was 
estimated  that IO6 rat  serosal  mast cells contained 2.4 5 0.4 
REENTION TIME lmln 1 
FIG. 1. HPLC of a chondroitinase ABC digest of density 
gradient-purified proteoglycans from rat serosal mast cells. 
The retention  times of the standard disaccharides ADi-4S (4S),  ADi- 
diSB ( B ) ,  and ADi-diSE ( E )  are indicated. 
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FIG. 2. Fluorescence (A, B )  and paired Nomarski interference microscopy (A’, B’) photomicrographs 
of permeabilized rat serosal mast cells stained with anti-glycosaminoglycan monoclonal antibodies. 
Cells  were treated  with  chondroitinase ABC and  then  incubated  with  either  anti-chondroitin  sulfate ( A )  or anti- 
keratan sulfate ( B )  monoclonal antibodies before being stained with fluorescein-conjugated F(ab’)2 goat anti- 
mouse IgG. The arrows in panel A’ identify two cells that  failed to fluoresce and are not seen in panel A. 
Magnification, X 1043. 
I 
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FIG. 3. Immunofluorescence of permeabilized, chondroitin- 
ase ABC-treated rat serosal mast cells stained with dilutions 
of unabsorbed anti-chondroitin sulfate 512912-B-6 monoclo- 
nal antibody (O), 512912-B-6 after absorption with heparin- 
agarose (W), or 512912-B-6 after absorption with nontreated 
(0) or chondroitinase ABC-treated (0) rat chondrosarcoma 
chondroitin sulfate proteoglycan coupled to Sepharose 4B. 
The binding of undiluted,  unabsorbed  antibody  is  indicated by the 
asterisk. Data  are  from  one  representative  experiment. 
pg (mean f range, n = 2) of chondroitin  sulfate. 
Intracellular  Detection  by  Immunofluorescence Microscopy 
of Chondroitin  Sulfate in Rat Serosal Mast Cells-Incubating 
permeabilized, chondroitinase  ABC-treated rat serosal mast 
cells with a saturating  amount of the anti-chondroitin  sulfate 
5/29/2-B-6 monoclonal antibody and  then with fluorescein- 
ated  F(ab’)2 goat anti-mouse IgG resulted in the  staining of 
91 f 4.5% (mean f S.D., n = 3) of the cells; the  intensity of 
staining ranged from dim to extremely bright (Fig. 2 A ) .  The 
fluorescence was intracellular and granular in all positive 
cells. The specificity of the 5/29/2-B-6 monoclonal antibody 
for the  unsaturated double bond created  in the chondroitin 
sulfate glycosaminoglycan after  treatment with  chondroitin- 
ase ABC  was confirmed in  situ by the finding that permeabil- 
ized cells not treated with chondroitinase ABC failed to 
exhibit fluorescence. Permeabilized, chondroitinase ABC- 
treated mast cells incubated with the anti-keratan sulfate 
antibody also did not  stain (Fig. 2B). No fluorescent staining 
was detected when the permeabilized cells were treated with 
large amounts of heparinase before the interaction with the 
anti-chondroitin  sulfate monoclonal antibody. This excluded 
the possibility that a heparinase contaminant  in  the chon- 
droitinase ABC preparation was creating  a determinant from 
heparin that was recognized by the  anti-chondroitin sulfate 
monoclonal antibody. 
The specificity of the antibody-mediated fluorescence was 
also confirmed by absorption with solid-phase proteoglycans 
of an  amount of 5/29/2-B-6 antibody that gave maximal, but 
just  saturating, fluorescence staining of permeabilized, chon- 
droitinase ABC-treated rat serosal mast cells. The relative 
amount of residual affinity-absorbed  antibody was determined 
in each case by measuring its ability to mediate staining of 
rat serosal mast cells. When the 5/29/2-B-6 antibody was 
absorbed with chondroitinase ABC-digested chondrosarcoma 
chondroitin  sulfate proteoglycan coupled to Sepharose,  a 1:8 
dilution of the absorbed antibody preparation  stained only 
3.7 f 2.1% (mean f S.D., n = 3) of the  rat serosal mast cells 
(Fig. 3). Sixty-nine f 11%  (mean f S.D., n = 3) of the cells 
stained  after incubation with an identical  dilution of unab- 
sorbed 5/29/2-B-6 antibody. An equal amount of the 5/29/2- 
B-6 antibody that  had been absorbed with non-chondroitinase 
ABC-treated proteoglycan and diluted 1% stained 57 f 8.5% 
(mean f S.D., n = 3) of the  rat serosal mast cells, whereas a 
1:8 dilution of antibody absorbed with heparin-agarose under 
identical  conditions stained 70 f 10% (mean k S.D., n = 3) 
of the cells. Further dilution of the latter three antibody 
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preparations to 1:32 resulted in the staining of 35 +. 15%, 20 
-+ 5.7%, and 32 f 17% (mean f S.D., n = 3) of the cells, 
respectively, which  was comparable to  the activity of a 1:2- 
1:4 dilution of the monoclonal antibody following absorption 
with chondroitinase ABC-digested solid-phase chondroitin 
sulfate proteoglycan (Fig. 3). 
DISCUSSION 
Through the use of chemical and immunologic approaches, 
this study establishes that rat serosal mast cells contain 
chondroitin  sulfate proteoglycans that  are similar to  the novel 
proteoglycans that can be 35S-labeled ex uiuo in  rat mucosal 
mast cells. These highly sulfated chondroitin sulfate pro- 
teoglycans are rich in the disulfated disaccharides Di-diSB 
(iduronic acid-2-SO4+GalNAc-4-SO4) and Di-diSE (GlcA- 
GalNAc-4,6-diS04) (Fig. 1). Quantification of the chondroitin 
sulfate glycosaminoglycans by measurement of the  unsatu- 
rated disaccharides released by chondroitinase ABC treat- 
ment of the density gradient-purified proteoglycans revealed 
that lo6 rat serosal mast cells contain 2.4-4.5 gg of chondroitin 
sulfate proteoglycans, compared to a reported heparin proteo- 
glycan content of more than 20  pg per lo6 cells.  Upon isolation 
and radiolabeling with [35S]sulfate in uitro, rat serosal mast 
cells synthesize proteoglycans that contain heparin glycos- 
aminoglycans but  not  chondroitin  sulfate glycosaminoglycans 
(I) ,  although biosynthesis of over-sulfated chondroitin sulfate 
can be observed in the presence ofp-nitrophenyl-P-D-xyloside 
(9). Thus, either the  rat serosal mast cell synthesizes chon- 
droitin  sulfate proteoglycans at  an earlier stage of its differ- 
entiation or there is a  preferential suppression of chondroitin 
sulfate  synthesis when the cells are placed in  short-term  tissue 
culture. 
Using a mouse IgG, monoclonal antibody prepared to chon- 
droitinase  ABC-treated bovine nasal cartilage proteoglycan, 
we determined by intracellular fluorescence microscopy that 
at least 91% of the permeabilized and chondroitinase ABC- 
treated cells in the rat serosal mast cell preparations con- 
tained  chondroitin  sulfate proteoglycans (Fig. 2.4).  The  pat- 
tern of staining of the cells with the anti-chondroitin  sulfate 
monoclonal antibody indicated that these proteoglycans were 
stored in the secretory granules of the cells. The in situ 
specificity of this monoclonal antibody for chondroitin  sulfate 
glycosaminoglycans was limited to permeabilized, chondroi- 
tinase  ABC-treated rat serosal mast cells (Fig. 2 . 4 ) .  No fluo- 
rescence was observed in permeabilized, non-chondroitinase 
ABC-treated cells or in permeabilized, heparinase-treated 
cells. Solid-phase absorption of the antibody with chondroi- 
tinase ABC-digested chondroitin sulfate proteoglycan effec- 
tively abrogated subsequent binding to permeabilized, chon- 
droitinase ABC-treated rat serosal mast cells (Fig. 3) .  How- 
ever, solid-phase absorptions with equivalent amounts of 
either  non-chondroitinase ABC-digested chondroitin  sulfate 
proteoglycan or heparin did not reduce in situ binding to 
permeabilized and  chondroitinase ABC-treated mast cells, as 
assessed by dilution analysis of absorbed antibody prepara- 
tions compared with unabsorbed antibody (Fig. 3) .  Nonspe- 
cific absorption of IgG  molecules and nonspecific binding of 
the secondary, fluorescein-conjugated antibody to  the secre- 
tory granules were ruled out because the mouse IgG,  mono- 
clonal antibody that is reactive with keratan  sulfate glycos- 
aminoglycans did not bind to permeabilized and  chondroitin- 
ase ABC-treated rat serosal mast cells (Fig. 2B). Although 
-91% of chondroitinase ABC-treated rat serosal mast cells 
exhibited intracellular fluorescence when stained with the 
anti-chondroitin  sulfate monoclonal antibody, there was con- 
siderable heterogeneity in  the intensity of staining from  cell 
to cell. This variation could be due to differential loss of the 
chondroitin  sulfate proteoglycans during the permeabilization 
and enzymatic steps, to differences in the susceptibility of the 
chondroitin sulfate proteoglycans in situ to degradation by 
chondroitinase ABC because of varied interactions with other 
cationic proteins in the secretory granules, or it could reflect 
different stages of mast cell maturation. 
The presence of both heparin and chondroitin sulfate gly- 
cosaminoglycans in highly purified, normal ex vivo serosal 
mast cells is  a novel finding. In an earlier study we demon- 
strated  that  the  rat basophilic leukemia-1 cell line, which by 
a number of criteria is homologous to  rat mucosal mast cells 
(la), synthesizes both  nitrous acid-degradable and chondroi- 
tinase ABC-degradable glycosaminoglycans (19, 20). As as- 
sessed by HPLC analysis of chondroitinase ABC-generated 
unsaturated disaccharides, the chondroitin sulfate of the  rat 
basophilic leukemia-1 proteoglycan is composed of Di-4S and 
Di-diSB (19). The presence of heparin  and chondroitin sulfate 
that is rich in Di-diSB, as well as Di-diSE, in freshly isolated 
rat serosal mast cells demonstrates that  the classification of 
subpopulations of rat mast cells by their proteoglycan phe- 
notype may  be  more accurately defined by the ratios of the 
constituent glycosaminoglycans rather  than by the absolute 
amount of a single glycosaminoglycan. 
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